APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3

NCT00138034

Last updated date
Study Location
Radboud University Nijmegen Medical Center
Nijmegen, Gelderland, 6500 HB, Netherlands
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Myocardial Infarction
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- TIMI-3 in infarct-related artery with a stentable lesion with 72 hours of thrombolysis for ST-elevation myocardial infarction

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Use of oral anticoagulants.


- Known intolerance to aspirin or clopidogrel.


- Bypass graft as infarct-related artery.


- Previously dilated infarct related artery.


- Significant left main stenosis.


- Unidentifiable culprit stenosis.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Myocardial InfarctionAPRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3
NCT00138034
  1. Nijmegen, Gelderland
ALL GENDERS
0+
years
MULTIPLE SITES
Myocardial InfarctionThe Use of Statins for Myocardial Death Prevention
NCT00772564
  1. Haifa,
ALL GENDERS
30 Years+
years
MULTIPLE SITES
Myocardial InfarctionImpact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction
NCT01176968
  1. Edmonton, Alberta
  2. Edmonton, Alberta
  3. Vancouver, British Columbia
  4. Vancouver, British Columbia
  5. Vancouver, British Columbia
  6. St. John's, Newfoundland and Labrador
  7. Toronto, Ontario
  8. Toronto, Ontario
  9. Chicoutimi, Quebec
  10. Chicoutimi, Quebec
  11. Sherbrooke, Quebec
  12. Brno,
  13. Hradec Kralove,
  14. Hradec Kralove,
  15. Olomouc,
  16. Olomouc,
  17. Praha 4,
  18. Praha 5,
  19. Toulouse, Cedex 4
  20. Dijon, Cedex
  21. Paris, Cedex
  22. Cannes,
  23. Creteil,
  24. Creteil,
  25. Evecquemont,
  26. Libourne,
  27. Pessac Cedex,
  28. Bad Krozingen,
  29. Berlin,
  30. Bonn,
  31. Bremen,
  32. Dortmund,
  33. Dortmund,
  34. Dresden,
  35. Goettingen,
  36. Hamburg,
  37. Hannover,
  38. Limburg,
  39. Mainz,
  40. Munich,
  41. Athens,
  42. Athens,
  43. Rio Patra,
  44. Budapest,
  45. Gyor,
  46. Nyiregyhaza,
  47. Zalaegerszeg,
  48. Amsterdam,
  49. Nieuwegein,
  50. Bydgoszcz,
  51. Olsztyn,
  52. Oswiecim,
  53. Wroclaw,
  54. Banska Bystrica,
  55. Bratislava,
  56. Martin,
  57. Nitra,
  58. Rimavska Sobota,
  59. Jerez de la Frontera, Cadiz
  60. Barcelona,
  61. Barcelona,
  62. Madrid,
  63. Madrid,
  64. Palma de Mallorca,
  65. Valencia,
  66. Blackpool, Lancashire
  67. Edinburgh, Lothian
  68. Swansea, Wales
  69. Birmingham,
  70. Cottingham Hull,
  71. Coventry,
  72. Dundee,
  73. Edinburgh,
  74. Leicester,
  75. Swansea,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3
Official Title  ICMJE A Multicenter Randomized Trial in the Prevention of Reocclusion Following Successful Thrombolysis for Suspected Acute Myocardial Infarction: An Invasive Versus a Conservative Strategy
Brief Summary

Reocclusion of the infarct artery is observed in about 30% of patients within three months after successful thrombolysis for acute myocardial infarction (MI). Reocclusion is associated with an increased risk of death, reinfarction and the need for revascularization. Even in the absence of clinical reinfarction, reocclusion results in impaired left ventricular (LV) recovery, leaving patients at increased risk of developing heart failure in the long-term. Prevention of reocclusion is therefore warranted. In previous trials, severity of the infarct related stenosis was the only independent predictor of reocclusion. With a lack of clinical predictors of reocclusion, many cardiologists therefore empirically favor routine revascularization after successful thrombolysis.

The APRICOT-3 will be the first randomized trial in the current era of improved angioplasty techniques to study the question of whether a routine invasive strategy after successful thrombolysis can reduce the incidence of reocclusion and subsequently improve clinical outcome and LV-function. After successful thrombolysis, patients will be randomized to either a routine invasive strategy or an ischemia-guided strategy. The investigators expect to demonstrate a lower reocclusion rate at the 6-month follow-up angiography (primary endpoint) and fewer associated events (death, reinfarction, revascularization, admissions for heart failure) in the routine invasive arm. In search of non-invasive parameters predictive of reocclusion, laboratory analysis of several coagulation and inflammatory markers will be performed. Finally, pooled analysis of all 3 APRICOT trials will focus on the identification of clinical predictors of reocclusion that can easily be obtained by history and physical examination.

Detailed Description Randomized controlled study of elective percutaneous coronary intervention (PCI) of an open culprit lesion after fibrinolysis for ST-elevation myocardial infarction (STEMI)
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Myocardial Infarction
Intervention  ICMJE Procedure: Percutaneous coronary intervention (PCI)
PCI with bare metal stent placement of the culprit lesion the in the infarct related artery
Other Name: bare metal stent placement
Study Arms  ICMJE
  • Active Comparator: Percutaneous coronary intervention (PCI)
    Stenting of the culprit lesion of the infarct related artery and aspirin and clopidorgel for at least 6 months
    Intervention: Procedure: Percutaneous coronary intervention (PCI)
  • Dual antiplatelet therapy
    Aspirin and clopidogrel for at least 6 months
    Intervention: Procedure: Percutaneous coronary intervention (PCI)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 29, 2012)
49
Original Enrollment  ICMJE
 (submitted: August 29, 2005)
400
Actual Study Completion Date  ICMJE February 2010
Actual Primary Completion Date January 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • TIMI-3 in infarct-related artery with a stentable lesion with 72 hours of thrombolysis for ST-elevation myocardial infarction

Exclusion Criteria:

  • Use of oral anticoagulants.
  • Known intolerance to aspirin or clopidogrel.
  • Bypass graft as infarct-related artery.
  • Previously dilated infarct related artery.
  • Significant left main stenosis.
  • Unidentifiable culprit stenosis.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE Child, Adult, Older Adult
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Netherlands
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00138034
Other Study ID Numbers  ICMJE APRICOT-3
2003B257 ( Other Identifier: Netherlands Heart Foundation )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Prof. Dr. F.W.A. Verheugt, Heartcenter, University Medical Center St. Radboud
Study Sponsor  ICMJE Heartcenter, University Medical Center St. Radboud
Collaborators  ICMJE
  • Netherlands Heart Foundation
  • The Interuniversity Cardiology Institute of the Netherlands
  • Pfizer
  • Sanofi
Investigators  ICMJE
Principal Investigator:Freek WA Verheugt, MD PhDRadboud University Nijmegen Medical Center
PRS Account Heartcenter, University Medical Center St. Radboud
Verification Date April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP